Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, January 2001, p. 112-118, Vol. 8, No. 1
Centro de Pesquisas René Rachou,
FIOCRUZ1 and Hospital das
Clínicas, Faculdade de Medicina, Universidade Federal de Minas
Gerais,2 Belo Horizonte and Faculdade de
Medicina do Triângulo Mineiro,
Uberaba,3 Minas Gerais, Brazil
Received 28 April 2000/Returned for modification 25 July
2000/Accepted 20 September 2000
Two functionally distinct antibodies, categorized as conventional
serology antibodies (CSA) and lytic antibodies (LA) have been described
in Chagas' disease, based on their ability to bind to fixed
epimastigotes (EPI) or live trypomastigotes (TRYPO), respectively. In
this study, the profile of immunoglobulin G (IgG) subclasses of CSA and
LA were analyzed by flow cytometry using serum samples from chronic
chagasic patients with the indeterminate (IND), cardiac (CARD), and
digestive (DIG) clinical forms of the disease. The results were
expressed as percentage of positive fluorescent parasites (PPFP) for
each sample. CSA showed a higher PPFP than LA for all samples. At serum
dilutions between 1:256 and 1:2,048, IgG1 anti-EPI was able to
distinguish chagasic from nonchagasic individuals. Different profiles
of IgG subclasses were observed for CSA and LA. IgG1 and IgG2 were the
main subclasses in CSA, whereas IgG1 and IgG3 were the predominant ones
in LA. The reactivity of IgG2 anti-EPI was greater in IND and CARD than in DIG patients. Furthermore, a low level of IgG1 and IgG3 LA was
associated with most of the CARD patients. On the other hand, a high
level of IgG1 LA was associated with most of the IND patients. In
summary, our findings indicate the potential of IgG1 anti-EPI for
serological diagnosis of Chagas' disease, providing further evidence
for a protective role of LA, and show that IgG1 anti-live Trypanosoma cruzi TRYPO may be used to predict the risk of
cardiac damage in Chagas' disease.
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.1.112-118.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Anti-Trypanosoma cruzi Immunoglobulin G1 Can Be a
Useful Tool for Diagnosis and Prognosis of Human Chagas'
Disease
*
Corresponding author. Mailing address:
Laboratório de Doença de Chagas, Centro de Pesquisas
René Rachou, FIOCRUZ, Av. Augusto de Lima, 1715, Belo Horizonte
MG 30190-002 Brazil. Phone: 55 (31) 3295-3566, ext. 165. Fax: 55 (31)
3295-3115. E-mail: oamfilho{at}cpqrr.fiocruz.br.
Clinical and Diagnostic Laboratory Immunology, January 2001, p. 112-118, Vol. 8, No. 1
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.1.112-118.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shadomy, S. V., Waring, S. C., Chappell, C. L.
(2004). Combined Use of Enzyme-Linked Immunosorbent Assay and Flow Cytometry To Detect Antibodies to Trypanosoma cruzi in Domestic Canines in Texas. CVI
11: 313-319
[Abstract] [Full Text] -
Toledo, M. J. d. O., Bahia, M. T., Carneiro, C. M., Martins-Filho, O. A., Tibayrenc, M., Barnabe, C., Tafuri, W. L., de Lana, M.
(2003). Chemotherapy with Benznidazole and Itraconazole for Mice Infected with Different Trypanosoma cruzi Clonal Genotypes. Antimicrob. Agents Chemother.
47: 223-230
[Abstract] [Full Text] -
Martins-Filho, O. A., Eloi-Santos, S. M., Carvalho, A. T., Oliveira, R. C., Rassi, A., Luquetti, A. O., Rassi, G. G., Brener, Z.
(2002). Double-Blind Study To Evaluate Flow Cytometry Analysis of Anti-Live Trypomastigote Antibodies for Monitoring Treatment Efficacy in Cases of Human Chagas' Disease. CVI
9: 1107-1113
[Abstract] [Full Text]
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»